KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Receivables (2016 - 2026)

Bio-Rad Laboratories has reported Receivables over the past 18 years, most recently at $439.5 million for Q1 2026.

  • Quarterly Receivables changed 0.25% to $439.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $439.5 million through Mar 2026, changed 0.25% year-over-year, with the annual reading at $472.5 million for FY2025, 1.48% up from the prior year.
  • Receivables was $439.5 million for Q1 2026 at Bio-Rad Laboratories, down from $472.5 million in the prior quarter.
  • Over five years, Receivables peaked at $513.1 million in Q1 2023 and troughed at $438.4 million in Q1 2025.
  • The 5-year median for Receivables is $470.7 million (2022), against an average of $471.4 million.
  • Year-over-year, Receivables grew 18.91% in 2022 and then decreased 10.42% in 2024.
  • A 5-year view of Receivables shows it stood at $506.2 million in 2022, then decreased by 1.06% to $500.9 million in 2023, then dropped by 7.05% to $465.6 million in 2024, then grew by 1.48% to $472.5 million in 2025, then fell by 6.98% to $439.5 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Receivables are $439.5 million (Q1 2026), $472.5 million (Q4 2025), and $474.2 million (Q3 2025).